Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C25H18ClN5O2S2 |
| Molecular Weight | 520.026 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=C(C#N)C(C2=CC=C(OCCO)C=C2)=C(C#N)C(SCC3=CSC(=N3)C4=CC=C(Cl)C=C4)=N1
InChI
InChIKey=CITWCLNVRIKQAF-UHFFFAOYSA-N
InChI=1S/C25H18ClN5O2S2/c26-17-5-1-16(2-6-17)24-30-18(13-34-24)14-35-25-21(12-28)22(20(11-27)23(29)31-25)15-3-7-19(8-4-15)33-10-9-32/h1-8,13,32H,9-10,14H2,(H2,29,31)
| Molecular Formula | C25H18ClN5O2S2 |
| Molecular Weight | 520.026 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Capadenoson (BAY 68-4986) is a nonnucleoside agonist for the A1 Adenosine Receptor (A1AR) and the A2BAR. Capadenoson has undergone two Phase IIa clinical trials, initially in patients with atrial fibrillation and subsequently in patients with stable angina. Capadenoson has also been shown to decrease cardiac remodeling in an animal model of advanced heart failure and a capadenoson derivative, neladenoson bialanate, recently entered clinical development for the treatment of chronic heart failure. The therapeutic effects of capadenoson are currently thought to be mediated through the A1AR.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21185259 | https://www.ncbi.nlm.nih.gov/pubmed/21464936
Curator's Comment: # Bayer
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL226 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21185259 |
0.1 nM [EC50] | ||
Target ID: CHEMBL255 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28344125 |
8.94 null [pEC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Optimization of Thermolytic Response to A1 Adenosine Receptor Agonists in Rats. | 2017-09 |
|
| Capadenoson, a clinically trialed partial adenosine A1 receptor agonist, can stimulate adenosine A2B receptor biased agonism. | 2017-07-01 |
|
| Quantification of adenosine A(1) receptor biased agonism: Implications for drug discovery. | 2016-01-01 |
|
| Chronic therapy with a partial adenosine A1-receptor agonist improves left ventricular function and remodeling in dogs with advanced heart failure. | 2013-05 |
|
| The new oral adenosine A1 receptor agonist capadenoson in male patients with stable angina. | 2012-07 |
|
| Selective attenuation of norepinephrine release and stress-induced heart rate increase by partial adenosine A1 agonism. | 2011-03-28 |
|
| A1 adenosine receptor agonists and their potential therapeutic applications. | 2008-12 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22370739
In a randomized, double-blind, placebo-controlled, single dose-escalating, multicenter trial the effect of capadenoson at 1, 2.5, 5, 10, and 20 mg was compared versus placebo. Sixty-two male patients with stable angina were enrolled in the study. There was a consistent trend for heart rate reduction at comparable maximum work load in active treatment groups, with significant differences against placebo for 10 and 20 mg.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21464936
In isolated perfused hearts of Wistar and Spontaneously Hypertensive Rats (SHR), norepinephrine release was induced by electrical stimulation under control conditions (S1), and with capadenoson 60 nM (30 µg/l)
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:43:11 GMT 2025
by
admin
on
Mon Mar 31 18:43:11 GMT 2025
|
| Record UNII |
O519NVW73R
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29707
Created by
admin on Mon Mar 31 18:43:11 GMT 2025 , Edited by admin on Mon Mar 31 18:43:11 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000127411
Created by
admin on Mon Mar 31 18:43:11 GMT 2025 , Edited by admin on Mon Mar 31 18:43:11 GMT 2025
|
PRIMARY | |||
|
C87279
Created by
admin on Mon Mar 31 18:43:11 GMT 2025 , Edited by admin on Mon Mar 31 18:43:11 GMT 2025
|
PRIMARY | |||
|
9936489
Created by
admin on Mon Mar 31 18:43:11 GMT 2025 , Edited by admin on Mon Mar 31 18:43:11 GMT 2025
|
PRIMARY | |||
|
8723
Created by
admin on Mon Mar 31 18:43:11 GMT 2025 , Edited by admin on Mon Mar 31 18:43:11 GMT 2025
|
PRIMARY | |||
|
CHEMBL3235279
Created by
admin on Mon Mar 31 18:43:11 GMT 2025 , Edited by admin on Mon Mar 31 18:43:11 GMT 2025
|
PRIMARY | |||
|
O519NVW73R
Created by
admin on Mon Mar 31 18:43:11 GMT 2025 , Edited by admin on Mon Mar 31 18:43:11 GMT 2025
|
PRIMARY | |||
|
SUB33447
Created by
admin on Mon Mar 31 18:43:11 GMT 2025 , Edited by admin on Mon Mar 31 18:43:11 GMT 2025
|
PRIMARY | |||
|
544417-40-5
Created by
admin on Mon Mar 31 18:43:11 GMT 2025 , Edited by admin on Mon Mar 31 18:43:11 GMT 2025
|
PRIMARY | |||
|
DTXSID50969597
Created by
admin on Mon Mar 31 18:43:11 GMT 2025 , Edited by admin on Mon Mar 31 18:43:11 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET->PARTIAL AGONIST |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|